Literature DB >> 8353925

Luminal narrowing after percutaneous transluminal coronary angioplasty. A study of clinical, procedural, and lesional factors related to long-term angiographic outcome. Coronary Artery Restenosis Prevention on Repeated Thromboxane Antagonism (CARPORT) Study Group.

B J Rensing1, W R Hermans, J Vos, J G Tijssen, W Rutch, N Danchin, G R Heyndrickx, E G Mast, W Wijns, P W Serruys.   

Abstract

BACKGROUND: The renarrowing process after successful percutaneous transluminal coronary angioplasty (PTCA) is now believed to be caused by a response-to-injury vessel wall reaction. The magnitude of this process can be assessed by the change in minimal lumen diameter (MLD) at follow-up angiography. The aim of the present study was to find independent patient-related, lesion-related, and procedure-related risk factors for this luminal narrowing process. A model that accurately predicts the amount of luminal narrowing could be an aid in patient or lesion selection for the procedure, and it could improve assessment of medium-term (6 months) prognosis. Modification or control of the identified risk factors could reduce overall restenosis rates, and it could assist in the selection of patients at risk for a large loss in lumen diameter. This population could then constitute the target population for pharmacological intervention studies. METHODS AND
RESULTS: Quantitative angiography was performed on 666 successfully dilated lesions at angioplasty and at 6-month follow-up. Multivariate linear regression analysis was performed to obtain variables with an independent contribution to the prediction of the absolute change in minimal lumen diameter. Diabetes mellitus, duration of angina < 2.3 months, gain in MLD at angioplasty, pre-PTCA MLD, lesion length > or = 6.8 mm, and thrombus after PTCA were independently predictive of change in MLD. Overall prediction of the model was poor, however, percentage-correct classification for a predicted change between -0.1 to -0.4 mm was approximately 10%. Lesions showing no change or regression (change > -0.1 mm) and lesions showing large progression (< or = -0.4 mm) were more predictable (correct classification, 59.5% and 49.7%, respectively).
CONCLUSIONS: Renarrowing after successful PTCA as determined with contrast angiography is a process that cannot be accurately predicted by simple clinical, morphological, and lesion characteristics.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8353925     DOI: 10.1161/01.cir.88.3.975

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  10 in total

1.  Influence of diabetes on >10-year outcomes after percutaneous coronary intervention.

Authors:  Takatoshi Kasai; Katsumi Miyauchi; Kan Kajimoto; Naozumi Kubota; Takeshi Kurata; Hiroyuki Daida
Journal:  Heart Vessels       Date:  2008-05-17       Impact factor: 2.037

2.  The St Vincent Task Force for diabetes: report of the cardiovascular disease subgroup.

Authors:  B Pentecost; J S Yudkin
Journal:  Heart       Date:  1996-08       Impact factor: 5.994

Review 3.  The Clinical Significance of Physiological Assessment of Residual Ischemia After Percutaneous Coronary Intervention.

Authors:  Chandra P Ojha; Ahmed Ibrahim; Timir K Paul; Venkatachalam Mulukutla; Harsha S Nagarajarao
Journal:  Curr Cardiol Rep       Date:  2020-02-08       Impact factor: 2.931

4.  Anti-atherogenicity in women does not prevent restenosis after balloon angioplasty.

Authors:  T Watanabe; S Isoyama; A Nakamura; K Shirato; H Kubota; N Sekiguchi; F Sato; A Katoh; K Munakata; M Sugi; E Nozaki; O Nishioka; K Tamaki; K Akai; T Araki; K Yokoyama
Journal:  Heart Vessels       Date:  1997       Impact factor: 2.037

Review 5.  Revascularization for coronary artery disease in diabetes mellitus: angioplasty, stents and coronary artery bypass grafting.

Authors:  Doron Aronson; Elazer R Edelman
Journal:  Rev Endocr Metab Disord       Date:  2010-03       Impact factor: 6.514

6.  Long-term follow-up of coronary angioplasty in patients with diabetes compared with nondiabetics.

Authors:  B R G Brueren; J M Ten Berg; J C Kelder; M J Suttorp; E G Mast; E Bal; S M P G Ernst; H W T Plokker
Journal:  Neth Heart J       Date:  2004-04       Impact factor: 2.380

7.  Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF.

Authors:  A Rivard; M Silver; D Chen; M Kearney; M Magner; B Annex; K Peters; J M Isner
Journal:  Am J Pathol       Date:  1999-02       Impact factor: 4.307

Review 8.  Impact of impaired fractional flow reserve after coronary interventions on outcomes: a systematic review and meta-analysis.

Authors:  Mathias Wolfrum; Gregor Fahrni; Giovanni Luigi de Maria; Guido Knapp; Nick Curzen; Rajesh K Kharbanda; Georg M Fröhlich; Adrian P Banning
Journal:  BMC Cardiovasc Disord       Date:  2016-09-08       Impact factor: 2.298

9.  Coronary aspirate TNFα reflects saphenous vein bypass graft restenosis risk in diabetic patients.

Authors:  Theodor Baars; Thomas Konorza; Philipp Kahlert; Stefan Möhlenkamp; Raimund Erbel; Gerd Heusch; Petra Kleinbongard
Journal:  Cardiovasc Diabetol       Date:  2013-01-10       Impact factor: 9.951

10.  Anatomical and Technical Factors Influence the Rate of In-Stent Restenosis following Carotid Artery Stenting for the Treatment of Post-Carotid Endarterectomy Stenosis.

Authors:  Marine Gaudry; Jean-Michel Bartoli; Laurence Bal; Roch Giorgi; Mariangela De Masi; Pierre-Edouard Magnan; Philippe Piquet
Journal:  PLoS One       Date:  2016-09-09       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.